Dr Brian Lacy hosts Dr Carl Crawford of Weill Cornell to provide a comprehensive of the causes, risks, and treatment of Clostridioides difficile infection.
Dr Brian Lacy hosts Dr Carl Crawford of Weill Cornell to provide a comprehensive of the causes, risks, and treatment of Clostridioides difficile infection.
While the rate of inpatient colonoscopy has increased over the past decade and patients presenting with lower gastrointestinal bleeding (LGIB) tend to be sicker, the inpatient mortality rate has been dropping, according to an award-winning...
While the rate of inpatient colonoscopy has increased over the past decade and patients presenting with lower gastrointestinal bleeding (LGIB) tend to be sicker, the inpatient mortality rate has been dropping, according to an award-winning...
Dr Peery, from the University of North Carolina, discusses a study of the comparative effectiveness and harms of metronidazole-with-fluoroquinolone vs amoxicillin-clavulanate in treatment of diverticulitis among nonhospitalized patients.
Dr Peery, from the University of North Carolina, discusses a study of the comparative effectiveness and harms of metronidazole-with-fluoroquinolone vs amoxicillin-clavulanate in treatment of diverticulitis among nonhospitalized patients.
Dr Spiegel, director of health services research at Cedars-Sinai Medical Center in Los Angeles, discusses the persistent gastrointestinal symptoms seen in some patients after they recover from COVID-19.
Dr Spiegel, director of health services research at Cedars-Sinai Medical Center in Los Angeles, discusses the persistent gastrointestinal symptoms seen in some patients after they recover from COVID-19.
Anne Peery, MD, from the University of North Carolina, provides insight into the American Gastroenterological Association's recent update on the management of colonic diverticulitis.
Anne Peery, MD, from the University of North Carolina, provides insight into the American Gastroenterological Association's recent update on the management of colonic diverticulitis.
The findings underscore the substantial burden of steatotic liver disease and highlight the importance of recognizing its distinct subtypes in clinical practice.
The findings underscore the substantial burden of steatotic liver disease and highlight the importance of recognizing its distinct subtypes in clinical practice.
The study synthesizes data from 18 studies and more than half a million subjects to better characterize how nonbiologic factors contribute to MASLD burden.
The study synthesizes data from 18 studies and more than half a million subjects to better characterize how nonbiologic factors contribute to MASLD burden.
A new study examined 792,409 hospitalizations for Crohn's disease, of which 26,229 (3.3%) involved patients with coexisting metabolic dysfunction-associated steatotic liver disease.
A new study examined 792,409 hospitalizations for Crohn's disease, of which 26,229 (3.3%) involved patients with coexisting metabolic dysfunction-associated steatotic liver disease.
A new update from the US Multi-Society Task Force on Colorectal Cancer revises and refines recommendations for optimizing bowel preparation in colonoscopy.
A new update from the US Multi-Society Task Force on Colorectal Cancer revises and refines recommendations for optimizing bowel preparation in colonoscopy.
For practicing gastroenterologists, these results highlight the importance of proactive risk assessment and coordinated care strategies in MASLD populations, beyond liver-specific endpoints.
For practicing gastroenterologists, these results highlight the importance of proactive risk assessment and coordinated care strategies in MASLD populations, beyond liver-specific endpoints.
The study analyzed data from the Research Patient Data Registry between 2000 and 2023, focusing on patients aged 40 and older with a baseline FIB-4 score of 1.3 or higher.
The study analyzed data from the Research Patient Data Registry between 2000 and 2023, focusing on patients aged 40 and older with a baseline FIB-4 score of 1.3 or higher.
The TEMPO trial enrolled 40,000 adults aged 50–74 years and randomly assigned them to one of eight groups, testing combinations of a planning tool and deadline prompts of varying lengths.
The TEMPO trial enrolled 40,000 adults aged 50–74 years and randomly assigned them to one of eight groups, testing combinations of a planning tool and deadline prompts of varying lengths.